Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of RY_SW01 cell injection for systemic sclerosis
CTR20261234Phase 3Active
- Sponsor
- Ruiyuan Biotech
- Start
- Apr 2026
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 89zr-oxine-ry_sw01 in systemic sclerosis (SSc), sponsored by Ruiyuan Biotech. Started Apr 2026; status: active.
02
Drugs
89zr-oxine-ry_sw01
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on CTR20261234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261234.